[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. --------------------------------------------------------------- [707% Growth For American Lithium Company After They Fight Back Against China]( [They've Already Seen 707% Growth In 2021, And That Could Just Be The Start]() --------------------------------------------------------------- July 8, 2022 From the desk of the Editor (5 Dday Gainers Report) Dear Reader, We just identified 7 Five Day Gainers. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [The U.S. Solution to China's Copper Grab]() China consumes 54% of the world's copper. Yet China mines only 8% of its copper needs, while plundering Africa, Latin America and South America for copper. The U.S. is left scrambling for new copper sources. But there's a North American copper sweet spot overlooked by China – for now. [Find Out Where This Copper Hotspot Is and How You Can Benefit]( = --------------------------------------------------------------- [Avadel Pharmaceuticals, AVDL]( Recent Analyst Action: Ami Fadia, analyst at Needham, reiterates coverage on [Avadel Pharmaceuticals (AVDL)](in the Healthcare sector with a Buy rating and a price target of $6 (1 week ago). - Recent Price: $4.63 - Average Analyst Price Target: $10.60 (128.94%) - Market Cap: $252.96M [TipRanks.com]( also reports that [Avadel Pharmaceuticals](currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.60. The target pricing ranges from a high forecast of $19.00 down to a low forecast of $2.00. [Avadel Pharmaceuticals (AVDL)]()’s last closing price was $4.63 which would put the average price target at $10.60. Here are 3rd party ratings for [AVDL](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 36% (89 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Gold explodes past $2,000, here's what's next]( what feels like nearly a decade of disappointing returns, gold is entering a major bull market. You can get started today for less than $10. --------------------------------------------------------------- [Microstrategy, MSTR]() Recent Analyst Action: Brent Thill, analyst at Jefferies, reiterates coverage on [Microstrategy (MSTR)]()in the Technology sector with a Hold rating and a price target of $215 (2 weeks ago). - Recent Price: $229.25 - Average Analyst Price Target: $539.33 (135.26%) - Market Cap: $2.48B [TipRanks.com]( also reports that [Microstrategy]()currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $539.33. The target pricing ranges from a high forecast of $950.00 down to a low forecast of $215.00. [Microstrategy (MSTR)]()’s last closing price was $229.25 which would put the average price target at $539.33. Here are 3rd party ratings for [MSTR](=): - TipRanks.com: Strong Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Strong Sell, Bottom 40% (150 out of 251) [Click here for chart >>]() -------------------------------------------------------------------------- [Verrica Pharmaceuticals, VRCA]( Recent Analyst Action: Serge Belanger, analyst at Needham, reiterates coverage on [Verrica Pharmaceuticals (VRCA)]()in the Healthcare sector with a Hold rating (1 week ago). - Recent Price: $3.19 - Average Analyst Price Target: $11.50 (260.50%) - Market Cap: $119.35M [TipRanks.com](=) also reports that [Verrica Pharmaceuticals](currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $11.50. The target pricing ranges from a high forecast of $16.00 down to a low forecast of $4.00. [Verrica Pharmaceuticals (VRCA)](’s last closing price was $3.19 which would put the average price target at $11.50. Here are 3rd party ratings for [VRCA](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Top 36% (89 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Holy Cow, Only $19!](=) Hi, my name is Jeff Clark. For the past 36 years, I've shown people from all walks of life how to make money in the markets. Retired stockbrokers... presidents of companies... people with almost no financial experience... and everything in between. But I haven't done it the usual way… My method is different. It's unlike anything you’ve probably ever seen before. [We're unveiling it right now for just $19.]( That's the lowest price my publisher has EVER offered for a trading research service… And it won't be available for long. Watch a '10-second live demo' of this method to see how it works." [Watch Now]( --------------------------------------------------------------- [Oramed Pharmaceuticals, ORMP]( Recent Analyst Action: Nathan Weinstein, analyst at Aegis Capital, reiterates coverage on [Oramed Pharmaceuticals (ORMP)](in the Healthcare sector with a Buy rating and a price target of $30 (1 month ago). - Recent Price: $7.24 - Average Analyst Price Target: $31.00 (328.18%) - Market Cap: $219.04M [TipRanks.com]( also reports that [Oramed Pharmaceuticals](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $31.00. The target pricing ranges from a high forecast of $32.00 down to a low forecast of $30.00. [Oramed Pharmaceuticals (ORMP)]()’s last closing price was $7.24 which would put the average price target at $31.00. Here are 3rd party ratings for [ORMP](): - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: n/a, n/a [Click here for chart >>]() -------------------------------------------------------------------------- [Cardiff Oncology, CRDF]() Recent Analyst Action: Joseph Catanzaro, analyst at Piper Sandler, reiterates coverage on [Cardiff Oncology (CRDF)](in the Healthcare sector with a Buy rating and a price target of $7 (1 month ago). - Recent Price: $3.23 - Average Analyst Price Target: $12.67 (292.26%) - Market Cap: $135.11M [TipRanks.com]() also reports that [Cardiff Oncology]()currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.67. The target pricing ranges from a high forecast of $22.00 down to a low forecast of $7.00. [Cardiff Oncology (CRDF)]()’s last closing price was $3.23 which would put the average price target at $12.67. Here are 3rd party ratings for [CRDF](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 31% (78 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Notorious "Crypto Hater" drops bombshell: "Don't buy ANY Bitcoin before you see this expose..."]() Millionaire Trader who managed $200 Million for the Silicon Valley Elite reveals, for the first time ever… "How I trade Bitcoin* - using my stock brokerage account - for the chance to make 3-times... 5-times... even 10-times more money than any of the crypto HODLERs out there!" *No crypto wallets or crypto exchanges are needed... No previous experience. This 3-second “Boomer” crypto move works whether Bitcoin goes up or down. [Click here - this LIVE demonstration reveals how he does it.]() --------------------------------------------------------------- [Oak Street Health, OSH]() Recent Analyst Action: Kevin Fischbeck, analyst at Bank of America Securities, reiterates coverage on [Oak Street Health (OSH)](=)in the Healthcare sector with a Sell rating and a price target of $18 (3 weeks ago). - Recent Price: $23.7 - Average Analyst Price Target: $27.09 (14.30%) - Market Cap: $5.76B [TipRanks.com](=) also reports that [Oak Street Health]()currently has 12 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $27.09. The target pricing ranges from a high forecast of $33.00 down to a low forecast of $18.00. [Oak Street Health (OSH)]()’s last closing price was $23.7 which would put the average price target at $27.09. Here are 3rd party ratings for [OSH](=): - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Bottom 33% (168 out of 251) [Click here for chart >>](=) -------------------------------------------------------------------------- [CS Disco, LAW]() Recent Analyst Action: Doug Bruehl, analyst at J.P. Morgan, reiterates coverage on [CS Disco (LAW)]()in the Technology sector with a Buy rating and a price target of $55 (1 month ago). - Recent Price: $24.86 - Average Analyst Price Target: $38.00 (52.86%) - Market Cap: $1.41B [TipRanks.com]( also reports that [CS Disco]()currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $38.00. The target pricing ranges from a high forecast of $55.00 down to a low forecast of $28.00. [CS Disco (LAW)](=)’s last closing price was $24.86 which would put the average price target at $38.00. Here are 3rd party ratings for [LAW](): - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 44% (139 out of 251) [Click here for chart >>]() -------------------------------------------------------------------------- --------------------------------------------------------------- [Copper More Critical than Lithium?]() Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found. [See How You Can Benefit From New Copper Discoveries.](=) --------------------------------------------------------------- And there you have it--7 Five Day Gainers. Sincerely, Editor, MarketSectorDaily.com [Unsubscribe]( Sandpiper Marketing Group, LLC PO Box 407 Mt. Mourne, North Carolina 28123 United States (845) 803-0954 If you no longer wish to receive our emails, click the link below: [Unsubscribe]( Sandpiper Marketing Group, LLC PO Box 407 Mt. Mourne, North Carolina 28123 United States (845) 803-0954